

Minutes of Pre-bid meeting held on 31/10/2014 at 14:00 hr at RITES office for procurement of Tablet Buprenorphine 2 mg and 0.4 mg against: IFB No. RITES/MSM/NACP/15/2014

1. The following were present:-

I) From RITES

S/Shri

Prakash Mirani, GM/MSM

R K Sharma, JGM/MSM

Manoj Kumar Das, Manager/MSM

B. N. Meena, AM/MSM

III) Firms which attended the pre bid conference are as follows:

S. No.	Name of representative S/Shri	Name of Firm
1	Vishal Mahajan	M/s SAR Meditech Pvt. Ltd., Delhi
2	Sushil Sharma	M/s Verve Human Care Laboratories, Dehradun
3	Bhupinder Singh	M/s Biomedicare Labs Pvt. Ltd., New Delhi
	M. L. Shah	
4	B. A. Patil	M/s Rushan Pharma Ltd., Mumbai
5	Arvind Madan	M/s Modi-Mundipharma Pvt. Ltd., New Delhi
6	Arun Kr. Sharma	M/s Hospimax Healthcare Pvt. Ltd., New Delhi

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.

3. The issues raised during the pre bid meeting and clarifications are as under-

S. No.	Query Raised	Clarification
Section II. Bid Data Sheet		
1.	One of the participants mentioned that the tender issued for Tablet Buprenorphine is for "Next Three year's supplies" and the quantities of the Tablets for next three years is very high comparatively last year Tender and therefore requested to consider the 1/4 th to the the schedule quantity "as achieved an actual annual Production of specific or similar goods," instead of 1/3 rd of the Schedule quantity.	This criteria of "achieved an actual annual production of specific or similar goods" has been revised to at least 1/4 th of the schedule quantity. Please refer Amendment No. 1.
Section III: Schedule of Requirements		
2.	One of the participants has suggested to divide each schedule in multiple schedules to relax qualification criterias, to reduce bid security value and to ensure availability of drug by placing orders on multiple sources.	There will be no change
3.	One of the participants has suggested to procure the tendered quantity in three annual tenders instead of one tender to relax the eligibility	There will be no change

S. No.	Query Raised	Clarification
	conditions.	
Section V. Special Conditions OF Contract		
4.	<p>Performance Security – One participant has requested to reduce the performance security from 10% to 3% of the contract value as this procurement is for three years.</p> <p>Another participant has requested to reduce the performance security to 5% of contract value as the total value of procurement for three years is very large.</p>	<p>The requirement of Performance Security has been revised to 5% of contract value.</p> <p>Please refer Amendment No. 1.</p>
Section VII. Technical Specifications		
5.	<p>Point no 5 – <i>Buprenorphine tablets should be colorless, tasteless, easy to dissolve when taken sublingually, does not disintegrate easily on taking out from packing with hardness range from 1.5 to 3kg.</i></p> <p>One of the participants has mentioned that as per their experience hardness of individual tablets may vary slightly. Hardness should be calculated as average of 10 tablets. They have requested this limit to be changed to 1.5 to 4 kg instead of 1.5 to 3kg.</p>	There will be no change
6.	<p>Point no 6 – <i>The information regarding bioavailability of product should be quoted and probably it may be substantiated by relevant evidences. –</i></p> <p>Bioavailability is expressed in comparison to the injectable form of the same drug. Bioavailability of the tablet form is usually lower and that of Buprenorphine tablets in sublingual route is 30 to 50%. Thus, the criteria of Bioavailability is very broad and does not impose any check and balance on the quality of the product which might ultimately affect the daily dosage of the medicine and ultimately affect the per patient treatment cost to NACO.</p>	There will be no change

Meeting concluded with thanks to the participants for their active participation.